Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer. - Wikidata - wikimedia - TriplyDB

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.

http://www.wikidata.org/entity/Q36293034

about

RECQL5 cooperates with Topoisomerase II alpha in DNA decatenation and cell cycle progression Glutathione S-transferase M1 null genotype: lack of association with tumour characteristics and survival in advanced breast cancer.High-definition DNA methylation profiles from breast and ovarian carcinoma cell lines with differing doxorubicin resistance Associations between clinicopathological prognostic factors and pAkt, pMAPK and topoisomerase II expression in breast cancer.Overexpression of ErbB2 in cancer and ErbB2-targeting strategies.HER-2/neu and topoisomerase IIalpha in breast cancer.Predictive value of topoisomerase II alpha immunostaining in urothelial bladder carcinoma TOP2A amplification in the absence of that of HER-2/neu: toward individualization of chemotherapeutic practice in breast cancer Targeted therapy in breast cancer: the HER-2/neu gene and protein.Amplification and deletion of topoisomerase IIalpha associate with ErbB-2 amplification and affect sensitivity to topoisomerase II inhibitor doxorubicin in breast cancer.DNA topoisomerase IIalpha expression and the response toprimary chemotherapy in breast cancer.The significance of Epstein Barr virus (EBV) & DNA topoisomerase II alpha (DNA-Topo II alpha) immunoreactivity in normal oral mucosa, oral epithelial dysplasia (OED) and oral squamous cell carcinoma (OSCC).Resistance to chemotherapy in cancer: a complex and integrated cellular response.A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with breast cancer.Topoisomerase 2 alpha: a real predictor of anthracycline efficacy?Optimal adjuvant chemotherapy in breast cancer: selection of agents.Evaluation of HER-2/NEU protein expression in breast cancer by immunohistochemistry: an interlaboratory study assessing the reproducibility of HER-2/NEU testing.Aberrations of ERBB2 and TOP2A genes in breast cancer.Genomic predictors of response to doxorubicin versus docetaxel in primary breast cancer.Molecular profiling of invasive breast cancer by multiplex ligation-dependent probe amplification-based copy number analysis of tumor suppressor and oncogenes.HER-2 expression is a prognostic factor in patients with metastatic breast cancer treated with a combination of high-dose cyclophosphamide, mitoxantrone, paclitaxel and autologous blood stem cell support.Effect of HER2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the MAGIC trial.Topoisomerase II-alpha expression in different cell cycle phases in fresh human breast carcinomas.Genomic imbalances detected by comparative genomic hybridization are prognostic markers in invasive ductal breast carcinomas.The expression of the cytoskeletal focal adhesion protein paxillin in breast cancer correlates with HER2 overexpression and may help predict response to chemotherapy: a retrospective immunohistochemical study.Role of proliferation in HER2 status predicted response to doxorubicin.Can patients' likelihood of benefiting from primary chemotherapy for breast cancer be predicted before commencement of treatment?Topoisomerase IIalpha as a prognostic factor in mantle cell lymphoma.High topoisomerase IIalpha expression associates with high proliferation rate and and poor prognosis in oligodendrogliomas.HER2 positivity may confer resistance to therapy with paclitaxel in breast cancer cell lines.Topoisomerase II-alpha gene deletion is not frequent as its amplification in breast cancer.Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer.

P2860

Q24293748-41138C1B-DD10-47C6-88D2-9C40AE9539B7 Q24791151-8A695566-E20F-40EC-AF19-C3C4876A8514 Q28474284-02CD03EA-10FE-45C8-B72E-3303451C3719 Q33816025-60A4B600-5A56-4156-9783-DE16979FBE29 Q33931164-EFDE746D-F5A7-452E-9B5F-B020ACA43A43 Q35130680-6E0FAF84-747C-4E53-A2BD-C65EEDF77B83 Q35398592-B8777C48-88DD-4850-AD4C-6003EF71F23D Q35584659-A1F3942D-6340-4B9E-A954-8D5B7AD2252D Q35648508-E6263050-9DF8-4FB1-A20C-D41EC64028C4 Q35809752-F9AEB3F8-CD55-4057-AC1D-CE3899A72630 Q36648223-DEA9AE4A-09EF-432B-81D3-121CB2A6E6C6 Q37032422-53D97EE7-DBCC-4EB7-B160-DEF328242730 Q37079652-74DFB59C-DACF-4B13-988B-7A9575F50450 Q37458322-09505253-FEBB-461D-80AB-2A284F1E136B Q37989074-91A22D06-2DA6-4E18-B982-CC22A74AF8D3 Q38235713-30337B21-D093-4A26-B8A2-BEC8D83CA949 Q38455433-17BDF33C-C9F6-4A38-8613-60D5E86FA24D Q39769567-B9E553C9-B784-4C28-AF55-4F7F4D0BA8F2 Q42486311-5C35142D-B7D9-427C-8A6F-DE32A5C8193D Q43062153-32B4C9E0-2E1C-454F-A9A3-A9C2C4293998 Q43690747-EACF02E5-B2BB-4358-8E18-998CCE82AF87 Q43712233-7F4CF298-2A91-431E-9E18-BA60E172B94B Q43993916-33F78B6E-232B-4C06-AAF7-02B14885A7A2 Q44016601-F7F7726A-DE81-4F09-A218-5AD4A6A18163 Q44225442-358BBBDF-7EC1-4A82-9DCA-C7D97C5A38A3 Q44415276-53B540E8-B80A-4AA1-99E5-94BE778FB837 Q45023676-F5ECE082-9F20-4B83-9B05-C5AC17144AE8 Q47330973-DFA56E82-05FB-4852-80AC-59B612BB4430 Q49142324-BB5C0D3E-1633-4142-89F8-4D5593DF81AF Q50643855-CE2B430B-73F3-41CE-B14E-E71EFC9743CE Q53603097-22B891F4-5254-4502-9834-9EDAB8187AEA Q54577077-AFE50D3C-8833-4887-BD0B-D4304D070AC1

P2860

Predictive value of topoisomerase IIalpha and other prognostic factors for epirubicin chemotherapy in advanced breast cancer.

http://www.wikidata.org/entity/Q36293034

description

1998 nî lūn-bûn

@nan

1998年の論文

@ja

1998年学术文章

@wuu

1998年学术文章

@zh-cn

1998年学术文章

@zh-hans

1998年学术文章

@zh-my

1998年学术文章

@zh-sg

1998年學術文章

@yue

1998年學術文章

@zh

1998年學術文章

@zh-hant

name

Predictive value of topoisomer ...... apy in advanced breast cancer.

@ast

Predictive value of topoisomer ...... apy in advanced breast cancer.

@en

type

label

Predictive value of topoisomer ...... apy in advanced breast cancer.

@ast

Predictive value of topoisomer ...... apy in advanced breast cancer.

@en

prefLabel

Predictive value of topoisomer ...... apy in advanced breast cancer.

@ast

Predictive value of topoisomer ...... apy in advanced breast cancer.

@en

P1433

Q36293034-DB60A067-175C-402F-A70F-7DFBE42763B9

P1476

Q36293034-F04A8A9E-8E88-46A4-B7E0-BB3D9D2D8041

P2093

Q36293034-702D0CD7-8BCA-4A9A-95C9-C8317BDC6A58

Q36293034-C567D4DC-C17D-42F1-A10D-6D0EE7B3A157

Q36293034-E520E899-373F-409A-B732-B8A23A42E8E4

Q36293034-FA5EB697-1BAE-49F5-ADCD-EECC8092F7C9

P2860

Q36293034-01E72ECE-4F24-4D5D-85FE-EB6A59D57DA3

Q36293034-09F9689C-B6B3-4E69-B18E-23F615619BBE

Q36293034-135816C4-90D3-48ED-846E-C398F74B22BA

Q36293034-154B6D08-8351-4D2F-9DDC-7127D47C6C53

Q36293034-1A975735-47C3-4099-BE40-270B018801E7

Q36293034-1E163921-3B1F-4D0A-82E0-E47186623BB2

Q36293034-26ACE5BD-D971-4794-B161-BCE184EF466C

Q36293034-414EDD0F-B0B3-4FE6-9BF1-2A655924E0D8

Q36293034-4189C7A3-9C27-4D8B-B223-158CA74FE5C7

Q36293034-4326A66E-8A01-4B56-B751-FCCB36527246

P2888

Q36293034-309D781F-8037-48BF-A2CC-08F2B1F2A3BF

P304

Q36293034-DB50E246-4826-4D81-AB52-3C053C7AEF3B

P31

Q36293034-B43807B7-A0D3-40AD-B7D6-64CAE46F7CD6

P356

Q36293034-BF787CFA-818E-410F-9A43-933A9D24A2B6

P407

Q36293034-3DCB306B-27D7-4363-9D2A-B91CA0BD28BA

P433

Q36293034-02CD3378-13EC-4B1E-83DA-1833F04C2E0F

P478

Q36293034-240BB18F-49D7-4921-9C9E-A5F821D6EBF3

P577

Q36293034-AF47FE9F-70EF-4CCA-95BF-EB86F12B60AD

P5875

Q36293034-080159A6-22C7-48B1-B076-34E1C5F2759B

P698

Q36293034-FDE3CEAF-FDD5-4792-9F5B-556EA096ECD7

P921

Q36293034-9AEE66E4-5DD1-4F72-8DDB-DDD56F7F7BDE

P932

Q36293034-8CE8104F-6E8B-4B9B-9BD4-9821590F797D

P356

P1433

British Journal of Cancer

P1476

Predictive value of topoisomer ...... apy in advanced breast cancer.

@en

P2093

Holli K

http://www.w3.org/2001/XMLSchema#string

Isola JJ

http://www.w3.org/2001/XMLSchema#string

Järvinen TA

http://www.w3.org/2001/XMLSchema#string

Kuukasjärvi T

http://www.w3.org/2001/XMLSchema#string

P2860

Structure and function of type II DNA topoisomerases

Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years

Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals

Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway.

Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.

Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies.

Expression of topoisomerase IIalpha is associated with rapid cell proliferation, aneuploidy, and c-erbB2 overexpression in breast cancer

Response to mitoxantrone in advanced breast cancer: correlation with expression of c-erbB-2 protein and glutathione S-transferases.

Histological grade, elastosis, DNA ploidy and the response to chemotherapy of breast cancer

Do DNA ploidy and S-phase fraction in primary tumour predict the response to chemotherapy in metastatic breast cancer?

P2888

P304

2267-2273

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.1998.377

http://www.w3.org/2001/XMLSchema#string

P407

P433

12

http://www.w3.org/2001/XMLSchema#string

P478

77

http://www.w3.org/2001/XMLSchema#string

P577

1998-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260201745

http://www.w3.org/2001/XMLSchema#string

P698

9649144

http://www.w3.org/2001/XMLSchema#string

P921

P932

2150425

http://www.w3.org/2001/XMLSchema#string